Epstein-Barr virus (EBV) encoded latent membrane protein 1 (LMP1) is noted for its transforming potential. Yet, it also acts as a cytostatic and growth-relenting factor in Burkitt's lymphoma (BL) cells. The underlying molecular mechanisms of the growth inhibitory property of LMP1 have remained largely unknown. In this study, we show that LMP1 negatively regulates a major oncogene, TCL1, in diffuse large B-cell lymphoma (DLBCL) and BL cells. MicroRNA (miR) profiling of LMP1 transfectants showed that among others, miR-29b, is upregulated. LMP1 diminished TCL1 by inducing miR29b through C-terminus activation region 1 (CTAR1) and CTAR2. miR-29b locked nucleic acid (LNA) antisense oligonucleotide transfection into LMP1-expressing cells reduced miR-29b expression and consequently reconstituted TCL1, suggesting that LMP1 negatively regulates TCL1 through miR-29b upregulation. The miR-29b increase by LMP1 was due to an increase in the cluster pri-miR-29b1-a transcription, derived from human chromosome 7. Using pharmacological inhibitors, we found that p38 mitogen-activated protein kinase-activating function of LMP1 is important for this effect. The ability of LMP1 to negatively regulate TCL1 through miR-29b might underlie its B-cell lymphoma growth antagonistic property. As LMP1 is also important for B-cell transformation, we suggest that the functional dichotomy of this viral protein may depend on a combination of levels of its expression, lineage and differentiation of the target cells and regulation of miRs, which then directs the outcome of the cellular response.
Introduction
The highly efficient process of B-cell transformation induced by Epstein-Barr virus (EBV) is due to a concerted function of its nine latent proteins (Ku¨ppers, 2005) . The latent membrane protein 1 (LMP1) is one of the major effectors of this transformation (Kaye et al., 1993) . This viral membrane protein is transcribed from the BNLF1 open reading frame (Hudson et al., 1985) . LMP1 transforms rodent fibroblasts (Wang et al., 1985; Baichwal and Sugden, 1988) . In transfected Burkitt's lymphoma (BL) lines, LMP1 brings about profound cellular changes characterized by growth in clusters due to increased adhesion molecules expression and activated B-cell phenotype (Wang et al., 1988) . It mimics a constitutively active tumor necrosis factor receptor that acts through interaction with T receptor-associated factors (Lam and Sugden, 2003) .
On the basis of the latent gene expression in tumor and in the in vitro-infected cells, the viral latency is divided into three categories. In latency I, EBNA1 and LMP2A are expressed (Bell et al., 2006) . When LMP1 is expressed, along with the aforementioned viral proteins, such latent gene expression profile is called latency II. The third category, latency III, is represented by expression of all six virally encoded nuclear proteins and the three membrane proteins (Rowe et al., 1987) .
T-cell leukemia gene 1 (TCL1) was identified as an oncogene overexpressed in T-cell leukemia (Virgilio et al., 1993) . TCL1 transgenic mice develop B-cell malignancies such as Burkitt-like lymphoma, diffuse large B-cell lymphomas (DLBCLs), B-cell leukemias and follicular lymphomas (Bichi et al., 2002; Hoyer et al., 2002) . TCL1 is also expressed in human B-and T-cell-derived tumors (Said et al., 2001; Kiss et al., 2003) . The capacity of TCL1 to promote cell survival and growth has been attributed to its AKT-activating properties (Pekarsky et al., 2000) .
MicroRNAs (miRNAs) are 20-22 nucleotide long non-coding RNAs, and have emerged as powerful regulators of gene expression (Bartel and Chen, 2004) . The stem-loop-like miR precursors are cleaved by the nuclear enzyme Drosha. Subsequently, the cytoplasmic RNase III Dicer has an important role in generating the mature product that associates with RNA interference silencing complex. The mature miRNA binds to the 3 0 -untranslated region (UTR) of the target mRNA and inhibits its translation and/or promotes degradation (Bartel and Chen, 2004) . As far as pathological conditions are concerned, several miRNAs are now found either highly expressed in tumors or their expression is diminished in malignant cells (Calin and Croce, 2007) .
Interestingly, although LMP1 has growth-promoting effects in rodent fibroblasts (Wang et al., 1985; Baichwal and Sugden, 1988) , in BL lines it acts as a growth antagonist (Cuomo et al., 1992; Floettmann et al., 1996) . This growth inhibitory property of LMP1 in BL cells has remained largely uncharacterized. We recently showed that EBNA2 and LMP1 negatively influenced TCL1 expression (Boccellato et al., 2007) . The identification of miR-29b and miR-181b as negative regulators of TCL1 prompted us to ask whether the negative regulation of TCL1 by LMP1 involves upregulation of any of these two miRs (Pekarsky et al., 2006) . In this study, using a series of LMP1-transfected B-lymphoma cells, we show that this viral protein downregulates TCL1 by positively regulating miR-29b.
Results
LMP1 expression in DLBCL cells reduces TCL1 protein as well as TCL1 mRNA Our previous data suggested that LMP1 downregulates TCL1 in U2932 DLBCL cells (Boccellato et al., 2007) . We reconfirmed the data shown here in Figure 1a . Moreover, an analysis of TCL1 transcripts by real-time PCR showed that LMP1 affects TCL1 mRNA (Figure 1b ).
MiR profiling of U2932 DLBCLs transfected with LMP1
Recently, Pekarsky et al. (2006) experimentally verified that miR-29b and miR-181b could target TCL1 expression, both transcriptionally and at the protein level. It is important to point out that according to major on-line algorithms, TCL1A (NM_021966) but not TCL1B (NM_199206) 3 0 -UTR contains the miR-29b target site. This prompted us to ask whether LMP1 might negatively regulate TCL1 through these two miRs. To this end, a miR expression microarray profile of the control vector-transfected U2932 and its LMP1-transfected counterpart, U2932 LMP1 cl-3 was analyzed.
A schematic representation of the miR profile of U2932 LMP1 cl-3 is shown in Figure 2 . Three different RNA preparations were generated from the control and LMP1-expressing cells. Fluorescence signals observed in triplicate array features at a level two-fold that of background were considered to be indicative of miRNA expression. Expression of a total of 462 miRs was investigated. miR-29a/b/c and miR-146a are among those miRs that are highly induced by LMP1. Previous findings that LMP1 induces miR-146a are consistent with our results (Motsch et al., 2007; Cameron et al., 2008) . Supplementary Figure 1 shows the heat map of the miR profile. The absence of miR-181b here suggests that this miR may not be affected by LMP1. The expression of some of the miRs seen on the array was further verified by northern blots (Supplementary Figure 2) . In addition, we investigated whether miR146a upregulation by LMP1 might influence TCL1 expression. Supplementary Figure 3 shows that transfection of LNA-antimiR-146a oligo into U2932LMP1 expressor did not reconstitute TCL1 expression, in spite of the reduction in miR-146a expression. These data are also consistent with the fact that miR-146a-binding site is absent in the 3 0 -UTR of TCL1 gene, according to four major on-line algorithms.
TCL1 and miR-29b expression in EBV-carrying latency III expressors and in vitro-infected convertants As mentioned earlier, latency I and III profiles of viral gene expression are distinguished by the expression of LMP1 and EBNA2-6 in the latter. We thus asked whether LMP1-expressing latency III cells might have diminished TCL1 expression. Figure 3a shows that, indeed, cells with latency III profile had lower TCL1 protein expression in comparison with the latency I expressors. The lower TCL1 in latency III cells was further correlated with higher miR-29b. In addition, three EBV-negative B-cell lines, U2932, Bjab and Ramos, were infected in vitro with a recombinant Akata EBV LMP1 regulates TCL1 through miR-29b E Anastasiadou et al strain of EBV. Figure 3b shows that high LMP1-expressing convertants of U2932 and Ramos had a more pronounced TCL1 protein reduction. A majority of these EBV-infected clones with lower TCL1 showed an increased miR-29b (Figure 3c ), whereas Bjab EBVconverted clones showed only a marginal increase. The increase in miR-29b was slightly more marked when tested by quantitative real-time PCR (Supplementary  Figure 4) .
TCL1 and miR-29b expression in LMP1-transfected EBV-negative B-lymphoma cell lines To directly show that LMP1 alone is sufficient to reduce TCL1 expression, in addition to the U2932 DLBCL cells, EBV-negative B-lymphoma lines Bjab and Ramos were transfected with LMP1. Figure 4a shows that LMP1 expression in Bjab and Ramos cell lines was associated with diminished TCL1 expression. Subsequently, we analyzed miR-29b in the LMP1 transfectants. Figure 4b shows that LMP1 induced miR-29b expression in U2932, Bjab and Ramos LMP1 transfectants. The lower panel shows densitometric analysis of the northern blots. In Bjab LMP1 transfectants, the increase in miR-29b was only marginal. To investigate whether additional mechanisms might be involved in TCL1 reduction in U2932, Bjab and their respective LMP1 expressors, four different approaches, namely, the regulation of TCL1 promoter, proteosomal degradation, TCL1 mRNA stability and expression of miR-34b*, which was recently shown to regulate TCL1 expression (Cardinaud et al., 2009) , were employed and the results are shown in Supplementary Figure 5 . In Bjab LMP1 expressor, miR-34b* was expressed at higher levels. The increase in TCL1 in MG132-treated Bjab LMP1 transfectant is most likely related to the reduced expression of LMP1 in the treated cells. Overall, these data suggest that with the exception of miR-34b* increase, the other three mechanisms could not significantly account for TCL1 reduction in Bjab LMP1 transfectant. EBV LMP1 regulates TCL1 through miR-29b E Anastasiadou et al miR-29b1 negatively regulates TCL1 and LNA anti-miR-29b reverses LMP1-mediated miR-29b increase and TCL1 decrease In order to study the LMP1, miR-29b and TCL1 regulatory circuit, it is important to show that miR-29b can indeed downmodulate TCL1 expression in our experimental model system of DLBCL. To this end, we transfected an expression vector pMIF-cGFP-Zeo hsa-miR-29b1 and the corresponding vector control into U2932 cells. Figure 5a shows expression of miR-29b1 in the transfected clones. TCL1 expression, as expected, was downmodulated. b-Actin expression was uninfluenced in the miR-29b-transfected U2932 cells ( Figure 5b ). LNA oligonucleotides antagonize miR expression in an antisense manner. In order to investigate whether TCL1 Figure 5 Transfection of miR-29b1 expression vector negatively affects T-cell leukemia gene 1 (TCL1) expression in U2932 cells and locked nucleic acid (LNA) anti-miR-29b reverses latent membrane protein 1 (LMP1)-mediated miR-29b increase and reconstitutes TCL1 expression: An expression vector pMIF-cGFP-Zeo hsa-miR-29b1 and the corresponding vector control were electroporated into U2932 cells. Four zeocin resistant clones were isolated. (a) miR-29b expression was analyzed by northern blotting using an LNA-based miR-29b probe. (b) TCL1 was verified by immunoblotting using monoclonal antibodies on 15% SDS-polyacrylamide gels. (c) miR29b expression by northern blotting in LNA anti-miR-29b oligonucleotide-transfected U2932 LMP1 clone 3. A green fluorescent protein (GFP) containing plasmid was co-transfected to verify the transfection efficiency. As control, a scrambled oligonucleotide was used. The U2932 MPA vector control line was transfected with GFP and the scrambled oligonucleotide. U2 verification is used as loading and RNA quality control. (d) TCL1 protein expression in LNA anti-miR-29b transfected and control cells by immunoblotting. b-Actin is used as a loading control. The mean densitometric analysis is shown below the corresponding northern blots and immunoblots (( ± ) s.d., n ¼ 3).
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E Anastasiadou et al downregulation in LMP1-transfected cells is a direct result of miR-29b increase, we asked whether by antagonizing miR-29b expression through the corresponding antisense LNA oligonucleotide, the LMP1-mediated reduction of TCL1 could be reversed. To this end, LNA anti-miR-29b oligonucleotides (Exiqon) and green fluorescent protein (GFP) containing plasmids were co-transfected into U2932 LMP1 clone 3. As control, a scrambled oligonucleotide was used. Figure 5c shows that LMP1-induced miR-29b expression was severely reduced in the LNA anti-miR-29b-transfected but not in the scrambled control-transfected U2932 LMP1 clone 3. The middle panel shows U2 RNA expression in the corresponding samples, which is used as a loading control. The lowest panel shows densitometric analysis. Next, we tested whether TCL1 expression is reconstituted as a consequence of reduced miR-29b expression in LNA anti-miR-29b-transfected U2932 LMP1 clone 3. Indeed, TCL1 expression was enhanced in this LMP1 expressor when transfected with LNA anti-miR-29b (Figure 5d ). These data show that the increase in miR-29b expression by LMP1 is directly responsible for its negative effect on TCL1 expression.
Identification of LMP1 domains responsible for TCL1 reduction and miR-29b increase
The effector domains of LMP1 are located in the C-terminus activation region 1 (CTAR1) and CTAR2 of the protein (Floettmann and Rowe, 1997) . To define the regions of LMP1 responsible for the negative regulation of TCL1 and positive regulation of miR29b, we used LMP1 mutants where point mutations have been introduced into the CTAR1 and CTAR2. In Figure 6a , a schematic representation of these mutants is depicted. The wild-type (wt) and mutant LMP1 plasmids were transiently transfected into U2932 and SUDH4. Figure 6b , top panel, shows wt and mutated LMP1 expression in the transfected cells. The second panel shows that although the wt LMP1 downregulated TCL1, none of the mutants were able to do so. We further asked whether the lack of downregulation of TCL1 by LMP1 mutants was due to their inability to activate miR-29b expression. This was analyzed by realtime quantitative PCR. Figure 6b (lower panels) shows that although wt LMP1 increased miR-29b, the mutations introduced into CTAR1 and CTAR2 of LMP1 abolished its capacity to activate miR-29b expression in EBV LMP1 regulates TCL1 through miR-29b E Anastasiadou et al U2932 and SUDH4 cells. Collectively, these experiments suggest that both CTAR1 and CTAR2 have an important role in the negative regulation of TCL1 by LMP1 by influencing miR-29b expression.
Pharmacological inhibition of MAP kinase p38 and its correlation between TCL1 and miR-29b regulation by LMP1 Through CTAR1 and CTAR2, LMP1 triggers several signaling pathways such as p38 mitogen-activated protein (MAP) kinase, Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK), eventually leading to the activation of transcription factors such as nuclear factor-kB, STATs, AP-1, etc. (RaabTraub, 2001; Schultheiss et al., 2001) . The results in Supplementary Figure 6 that wt LMP1 but not mutated LMP1 activates p38 MAP kinase are consistent with previous data (Schultheiss et al., 2001) . The parental, vector-transfected and LMP1-expressing U2932 cells were treated with p38 MAP kinase-specific inhibitor, SB203580 (20 mM) for 24 and 48 h. These samples were tested for TCL1 expression. The treatment with the p38 MAP kinase inhibitor partially reconstituted TCL1 expression ( Figure 7a ). Next, we asked whether the time point at which the maximum TCL1 reconstitution was obtained after the SB203580 treatment was due to the reduction of miR-29b expression. Figure 7b shows that although the dimethyl sulfoxide-treated LMP1 transfectants maintained high miR-29b expression, the same cells when treated with SB203580 showed a decrease in this miR expression at 48 h. A corresponding densitometric analysis is shown below each panel. The inhibitory effect of SB203580 on pp38 is shown in Figure 7c . These data suggest that in the regulation of TCL1 and miR-29b by LMP1, the activation of signaling pathways involving p38 MAP kinase has a significant role. We did not observe any consistent and specific effect of inhibitors of the other signaling pathways (nuclear factor-kb, JNK, ERK) in the regulation of TCL1 (Supplementary Figure 7) in the cell lines studied.
LMP1 positively regulates pri-miR-29b1-a cluster at transcriptional level miR-29b exists in two identical forms, namely miR-29b1 and b2. miR-29b1 is located in the cluster pri-miR-29b1-a, on chromosome 7, and miR-29b2 is derived from the cluster pri-miR-29b2-c, on chromosome 1. In order to discern if LMP1 increases transcription of the primary transcript (Pri-miR), primers (both for reverse transcriptase-PCR (RT-PCR) and quantitative RT-PCR (qRT-PCR)) were designed from the pri-miR- EBV LMP1 regulates TCL1 through miR-29b E Anastasiadou et al 29b1-a and the pri-miR-29b2-c clusters such that they amplify a region flanking the Drosha cleavage sites (Figure 8a , Supplementary Table 1) . As seen in Figure 8b (RT-PCR) and Figure 8c (qRT-PCR), an increase in the pri-miR-29b1-a cluster was observed in the LMP1-transfected cells. These data provide two important insights, namely that the observed increase in miR-29b is most likely derived from the miR-29b1-a cluster and that such a regulation is the result of an increase in transcription of the primary transcript.
LMP1 affects growth of DLBCL cells in suspension cultures
We investigated here whether, similar to previous observations in BLs (Cuomo et al., 1992; Floettmann et al., 1996) , LMP1 could reduce growth of suspension cultures of transfected DLBCL cells. The cells were seeded at 2 Â 10 5 cells per ml and re-seeded at the original concentration on the fourth day, for two successive passages (Figures 9a and b) . The cells were counted daily and the viability was checked by Trypan blue exclusion test. As seen in Figure 9 , the vector transfected U2932 cells reached a cell density of B1.4 Â 10 6 /ml on the fourth day. The LMP1 expressing clones of U2932, on the other hand, grew more slowly and the cell density was inferior at B0.8 Â 10 6 /ml. The miR-29b-transfected U2932 cells (Figures 9a and b) had intermediate cell density, indicating that growth inhibition by LMP1 might involve additional cellular genes, including other miRs. The mutated LMP1 did not inhibit cell growth (Figure 9c ). U2932 LMP1 cl-3, transfected with antisense LNA anti-miR-29b oligonucleotide, grew better compared with the same LMP1 expressor transfected with a scrambled control (Figure 9d ).
Discussion
In this study, we show that LMP1 can simultaneously induce several miRs with noted tumor inhibitory capacity and suppress tumor-promoting miRs (He et al., 2005; O'Donnell et al., 2005; Chang et al., 2008) . Furthermore, we identified that LMP1, through its CTAR1 and CTAR2 domains, activates miR-29b expression to regulate TCL1 oncogene. LNA-mediated silencing of miR-29b in LMP1 transfectant and the consequent return of TCL1 expression suggest that LMP1 regulates TCL1 by increasing miR-29b. TCL1 mRNA was also reduced in LMP1-transfected cells. The fact that miR-29 regulates TCL1 protein as well as the corresponding mRNA has been previously reported (Pekarsky et al., 2006) . Taken together, these data provide an insight as to how this viral protein by downregulating TCL1 and by other, as-yet unidentified miR regulatory mechanisms, might start a chain of events that leads to profound changes in miR expression resulting in negative influence on the B-cell tumor growth.
Oncogene cooperation is a recurring theme in neoplasia development. Ras oncogene facilitates transformation by c-myc (Land et al., 1983) . The Abelson murine leukemia virus encoded v-abl cooperates with c-myc to accelerate plasmacytoma development in mice Figure 8 Transcriptional regulation of miR-29b1 by latent membrane protein 1 (LMP1). (a) The primers were designed to amplify the sequences between the Drosha-DGCR8 cleavage sites between the two miR stem-loops for both pri-miR 29b1-a and pri-miR-29b2-c clusters on chromosome 7 and 1, respectively. (b) Reverse transcriptase-PCR (RT-PCR) products were run on 2% agarose gels. (c) Quantitative real-time PCR for both pri-miR clusters. RPL32 was used as a housekeeping control ((±) s.d., n ¼ 3).
EBV LMP1 regulates TCL1 through miR-29b E Anastasiadou et al (Ohno et al., 1984) . The transformation of pre-B cells of Em-myc transgenic mice is enhanced by v-Ha-ras and v-raf (Alexander et al., 1989) . The BLs, on the other hand, are characterized by deregulated c-myc mainly owing to the 8:14 translocation, which juxtaposes c-myc to Ig heavy chain locus and high TCL1 expression (Said et al., 2001; Kiss et al., 2003) . TCL1 transgenic mice develop Burkitt-like lymphoma with high penetrance (Bichi et al., 2002; Hoyer et al., 2002) . Whether and how c-myc and TCL1 cooperate toward the development of BL is, however, not known. A recent study with an inducible c-myc experimental system identified that it contributes to tumorigenicity by suppressing tumor suppressor miRs (Chang et al., 2008) . Interestingly, a majority of those miRs repressed by c-myc, including miR-29b and miR-146a, were seen upregulated by LMP1 in our study. In contrast, LMP1 suppressed a number of miRs that are upregulatd by c-myc (O'Donnell et al., 2005) . Indeed, a previous study showed that LMP1 can negatively regulate c-myc (Floettmann et al., 1996) . A similar negative effect of LMP1 on c-myc in U2932 LMP1 expressors was observed by us (data not shown). Overall, these data are consistent with the previously described incompatibility between the latency III-driven transcription program and c-myc-driven growth program (Pajic et al., 2001) , and suggest that such an incompatibility might be due to differential and opposite regulation of the same miRs by c-myc and LMP1. Although further studies will be required to investigate how LMP1 downregulates c-myc and consequently alters miR expression, we would like to propose a scenario of oncogene cooperation in which suppression of miR-29b by c-myc (Chang et al., 2008) and the consequent positive regulation of TCL1 might be of critical significance in the pathogenesis of B-cell lymphomas with high c-myc and TCL1 expression.
This study highlights the positive regulatory role of LMP1 on miR-29b expression. This miR has been shown to inhibit tumorigenic growth by reducing expression of DNA methyl transferase (DNMT) (Fabbri et al., 2007) . Paradoxically, LMP1 has been shown to 
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E Anastasiadou et al activate DNMTs (Tsai et al., 2002) . If LMP1 induces miR-29b as shown here, DNMT expression should be adversely affected. This apparent paradox can be explained by the fact that LMP1 has opposite transforming effects in B cells and epithelial cells. Indeed, it was in the epithelial cell background that LMP1 increased DNMT expression (Tsai et al., 2002) Besides targeting TCL1 and DNMT, miR-29b negatively regulates another oncogene, MCL1 (Mott et al., 2007) . LMP1 was shown to increase MCL1 expression (Wang et al., 1996) . As such, this might seem discordant with our results. Notably although, the MCL1 induction by LMP1 was transient, and after 48 h, it returned to physiological levels that were seen before the transfection of LMP1 (Wang et al., 1996) . This transient nature of MCL1 induction by LMP1 was intriguing and the related mechanisms remained unclarified. In view of our findings, we suggest that LMP1-induced miR-29b expression might peak at day 2, eventually bringing down MCL1 expression. LMP1 transforms established rodent cell lines (Wang et al., 1985; Baichwal and Sugden, 1988) . The LMP1 transgenic mice develop B-cell lymphomas (Shair et al., 2007) . Furthermore, LMP1 null EBV mutants can grow in vitro provided the presence of feeder layer, but they fail to generate tumors in SCID mice (Dirmeier et al., 2003) . In established B lymphoma lines, LMP1 inhibits apoptosis through upregulation of BCL2 and A20 (Henderson et al., 1991; Laherty et al., 1992) . In addition, Kaye et al. (1993) have shown that this viral protein is essential for B-cell-transforming capacity of EBV. This is consistent with observations where LMP1 is expressed in lymphoproliferative diseases and B-cell lymphomas in immunocompromised patients (Horenstein et al., 1997; Ku¨ppers, 2005) . LMP1 thus has been widely studied for its oncogenic properties (Eliopoulos and Young, 2001) . Therefore, the lack of its expression in BL biospies (Tao et al., 1998) and growth antagonistic property attributed to LMP1 in B-lymphoma cell lines might seem paradoxical as such (Cuomo et al., 1992; Floettmann et al., 1996) . The reasons for LMP1 correlated reduced cellular proliferation might be several fold. It might be due to regulation of pro-apoptotic genes induced by LMP1 (Dirmeier et al., 2005) or reduction of gene expression through phosphorylation of elongation factor (Sandberg et al., 2000; Lam et al., 2004) . The present data that several tumor suppressor miRs are induced by LMP1 and the downregulation of TCL1 through miR-29b adds another mechanistic clue as to cytostasis provoked by this protein in B lymphoma cells. In this context, it is interesting to note that miR146a, upregulated by LMP1, is implicated in metastasis inhibition (Bhaumik et al., 2008; Hurst et al., 2009) . Taken together, this suggests that LMP1 can promote normal B-cell growth and that of murine fibroblasts, and yet is capable of inhibiting growth of B lymphoma cells. Most probably, the functional dichotomy of LMP1 may depend on a combination of lineage and differentiation window of the target cells and levels of its expression, which then directs the outcome of the cellular response.
Our data that both CTAR1 and CTAR2 domains of LMP1 regulate miR-29b through p38 MAP kinase are consistent with a previous study showing that both these domains have an important role in p38 MAP kinase induction (Schultheiss et al., 2001) . This adds to the growing evidence of the role of MAP kinases and their downstream transcription factor targets in the regulation of miR (O'Connell et al., 2007; Rahadiani et al., 2008) . In addition, BCR activation induces miR-155 through ERK and JNK but not p38 activation through a conserved AP-1 element . In contrast, miR-125a and miR-125b suppress phosphorylation of ERK1/2 and AKT (Scott et al., 2007) . The downregulation of miR-125b in the U2932 LMP1 expressors thus might explain how LMP1 activates ERK1/2 and AKT pathway. The TNF-a expression increase by LMP1 (Lay et al., 2003) is consistent with the downregulation of miR-125b, observed here, as this miR targets 3 0 -UTR of TNF-a (Tili et al., 2007) . In conclusion, we show that LMP1 brings profound changes in cellular miR expression. The regulation of miR-29b seems important in BL pathogenesis. As miR-29b is repressed by c-myc (Chang et al., 2008) , we postulate that c-myc positively regulates TCL1 by keeping in check miR-29b. LMP1, in contrast, by affecting c-myc expression (Floettmann et al., 1996; Kawanishi, 1997) may derepress miR-29b, which in turn downregulates TCL1. Further studies will be required to precisely characterize how LMP1 regulates miR-29b, but the ability of LMP1 to downregulate TCL1 expression by increasing miR-29b does provide a rationale for developing novel approaches for EBVassociated cancer therapy.
Materials and methods
Cells U2932 (Amini et al., 2002) and SUDH4 are EBV-negative DLBCLs. Eli, Rael, Akata, Mutu I cl-216 are type I BLs. B95-8, Mutu III cl-176 and LCLAKE are latency III expressors. Bjab and Ramos are EBV-negative B-cell lymphoma and BL, respectively. LCLAKE is a LCL derived after infecting peripheral B lymphocytes, with the recombinant EBV strain from AKATA BL. RPMI 8226 is a myeloma cell line used as negative control both for EBV and for TCL1.
Infection with a recombinant EBV strain Akata recombinant EBV producer cells were treated with anti-IgG as previously described (Maruo et al., 2001) . The supernatant containing recombinant EBV was used to infect EBV-negative cell lines. The infection was carried out for 2 h at 37 1C. The cells were resuspended in complete medium for 48 h before selection in 1 mg/ml of G418 for 3 weeks.
Immunoblotting
The expression of EBNA1, LMP1, c-myc, TCL1 and b-actin was verified by immunoblotting. Extracts equivalent to 10 6 cells were separated on discontinuous SDS-polyacrylamide gels and transferred to Protran (Amersham, Milano, Italy) filters. For TCL1, 15% SDS-polyacrylamide gels were used.
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The TCL1 monoclonal antibody (MBL International, Woburn, MA, USA) reacts with TCL1A but not TCL1B. Further details about the reagents used in immunoblotting can be found in Supplementary information.
LNA-based miRNA microarray Total RNA was prepared using TRIzol (Invitrogen, Milano, Italy) . Microarray experiments were performed using miR-CURY LNA microRNA Array Power Labeling Kit (Exiqon, Vedbaek, Denmark). The experimental sample (U2932 LMP1 cl-3) and a reference sample (U2932 MPA vector) were labeled in separate reactions with Hy5 and Hy3, respectively. More details can be found in Supplementary information.
Northern blotting RNA was extracted by standard TRIzol method and suspended in DNase and RNase-free water. Samples were run on 15% 7 M urea-acrylamide gels. Electrophoresis was carried out at 20 mA for about 3 h at room temperature. The oligonucleotides used as probes were purchased from Sigma (Milano, Italy). A more detailed northern blot protocol is included in Supplementary information.
Transfection and selection of U2932 cells expressing miR-29b1 and LMP1 U2932 cells were electroporated with an expression vector pMIF-cGFP-Zeo hsa-miR-29b1 carrying a precursor of miR-29b1 and a vector control (BioCat, Heidelberg, Germany). The LMP1 expression vector J132-G5 (a gift of Professor L Rymo, Gothenburg, Sweden) and the corresponding vector control pSVgpt were electroporated into U2932 and Bjab (230 V, 960 mF in 200 ml of phosphate-buffered saline). LMP1 mutants pSG5-LMP1.AAA-CTAR1-negative mutant, pSG5-LMP1.Y384G-CTAR2-negative mutant and pSG5-LMP1.AAAG-CTAR1/2-negative mutant, and the corresponding plasmid expressing the wild-type LMP1 were a kind gift of Dr Martin Rowe (Birmingham University Medical School, UK). The detailed electroporation and selection procedure is described in Supplementary information.
LNA anti-miR-29b oligonucleotide transfection
The U2932 LMP1 expressing clone 3 was co-transfected with 30 nM of LNA anti-miR-29b oligonucleotide (hsa-miR-29b miRCURYLNA, Exiqon) and 1 mg pEGFP-N1 vector (Clontech, Mountain View, CA, USA) by Lipofectamine 2000 (Invitrogen), whereas the U2932 MPA vector clone was transfected with either the GFP plasmid or a scrambled oligonucleotide. The transfection efficiency was B60%. After 48 h, the cells were harvested for total RNA and protein extraction.
Pharmacological treatment with p38 MAP kinase inhibitor
The DLBCL cell line, U2932, and its LMP1 transfected derivative were treated at a density of 3 Â 10 5 -5 Â 10 5 cells per ml with 20 mM of SB203580 (p38 MAP kinase inhibitor, Calbiochem, San Diego, CA, USA) for 24 and 48 h. The treated cells were harvested at the indicated time points and used for western and northern blot analysis.
RT-PCR
RNA was extracted using the TRIzol method (Invitrogen).
For cDNA synthesis, 6 mg of total RNA was treated with 1 ml of RNase-free DNase (RQ1, Promega, Milano, Italy) for 15 min at room temperature, followed by addition of 2 ml 10 Â stop mix, incubated for 10 min at 70 1C and subsequent immediate transfer on ice. The PCR amplification primers and conditions are described in Supplementary Table 1 and in detail in Supplementary information.
qRT-PCR Total RNA was isolated using TRIzol. For the verification of pri-miR-29b1-a and pri-miR-29b2-c expression, the reverse transcription was performed as mentioned above (and in the Supplementary Material and Methods). Each cDNA sample was split into three and used for qRT-PCR. The reaction was performed using SensiMix dT kit (Quantace, London, UK), SYBR green, 8 mM MgCl 2 and 330 nM of each primer on a real-time PCR system 7300 from Applied Biosystem (Monza, Italy). More details of the method can be found in Supplementary information. For verification of miR-29b, miR-146a and miR-34b*, TaqMan qRT-PCR (Applied Biosystems) was used and the details can be found in Supplementary Material and Methods.
